Stereotaxis (STXS): Customer relationships that signal a capital-equipment business with recurring consumable upside

Stereotaxis sells robotic magnetic navigation systems to hospitals and distributors and monetizes through capital equipment sales plus recurring consumables, software and service tied to its installed base. The company pursues a hybrid go-to-market—direct sales combined with distributor partnerships—to scale internationally while driving backend revenue from disposables and service contracts. For investors, the story is straightforward: long sales cycles and capital intensity on the front end, with higher-margin, recurring revenue on the back end. Learn more about the coverage and relationship mapping at https://nullexposure.com/.

The customer list investors need to read

Below I walk through every customer-related item surfaced in the results. Each entry is a concise, plain-English summary with a source note so you can follow the reporting yourself.

Shanghai MicroPort EP Medtech Co., Ltd. — exclusive China distribution announced (FY2025)

Stereotaxis announced a collaboration in which MicroPort EP will become the exclusive distributor of Robotic Magnetic Navigation technology for electrophysiology in China, positioning Stereotaxis to scale in a high-potential market through a local partner. Source: DiCardiology news report (March 2026) — https://www.dicardiology.com/content/stereotaxis-and-microport-ep-partner-commercialize-electrophysiology-robotics-china.

Shanghai MicroPort EP Medtech Co., Ltd. — prior collaboration referenced (FY2024)

Earlier coverage notes that Stereotaxis and MicroPort EP first inked a distribution and commercialization collaboration in 2021, establishing the commercial foundation that underpins the more recent exclusive arrangement. Source: The Robot Report (FY2024 coverage) — https://www.therobotreport.com/stereotaxis-surgical-robot-earns-regulatory-nod-in-china/.

Klinikum Fürth — German hospital launches robotic EP program (FY2026)

Stereotaxis announced the launch of a new robotic electrophysiology program at Klinikum Fürth, highlighting direct adoption by a major German hospital and reinforcing European program expansion. Source: GlobeNewswire press release (February 9, 2026) — https://www.globenewswire.com/news-release/2026/02/09/3234503/21634/en/klinikum-f%C3%BCrth-establishes-leading-robotic-heart-arrhythmia-program.html.

Klinikum Fürth — CEO comment on partnership (FY2026)

In parallel press coverage, Stereotaxis’ CEO David Fischel framed the Klinikum Fürth relationship as an effort to expand access to minimally invasive arrhythmia care in Germany, underscoring the company’s positioning as a partner to hospital systems. Source: GlobeNewswire press release with CEO commentary (February 2026) — https://www.globenewswire.com/news-release/2026/02/09/3234503/0/en/Klinikum-F%C3%BCrth-Establishes-Leading-Robotic-Heart-Arrhythmia-Program.html.

Penn Presbyterian Medical Center — first regional adopter in the Northeast (FY2025)

Penn Presbyterian became the first hospital in the U.S. Northeast to adopt Stereotaxis’ advanced robotic technology, signaling selective U.S. adoption at tertiary care centers willing to invest in cutting-edge electrophysiology tools. Source: DiCardiology report referencing the May 30, 2024 adoption (reported in FY2025 coverage) — https://www.dicardiology.com/content/stereotaxis-next-gen-endovascular-surgical-robot-receives-510k-clearance-fda.

University of Kansas Health System — first patients treated with Genesis system (FY2024)

Physicians at the University of Kansas Health System successfully treated initial patients with Stereotaxis’ Genesis system, demonstrating clinical rollout and early real-world utilization of the platform. Source: The Robot Report coverage (FY2024) — https://www.therobotreport.com/stereotaxis-surgical-robot-earns-regulatory-nod-in-china/.

What these relationships reveal about Stereotaxis’ operating model

Collectively the relationships show a company executing a two-tier strategy: sell capital systems to flagship hospital programs and partner with local distributors for broader geographic reach. This yields several investor-relevant characteristics:

• Contracting posture: Capital equipment is sold as part of larger hospital capital projects, often requiring financing or institutional approvals; Stereotaxis therefore operates with long sales cycles and project-level contracting. This is consistent with the company’s own disclosures that systems are typically purchased as part of larger capital projects.
• Concentration and materiality: No single customer accounts for more than 10% of revenue, so revenue is dispersed across hospitals and distributors; that reduces single-customer dependency while emphasizing volume and installed-base growth.
• Criticality and recurring revenue: The installed base drives recurring sales of disposable interventional devices, software and service—the practical source of margin expansion once systems are in place.
• Global footprint and route-to-market: Evidence supports a global go-to-market—direct hospital placements plus exclusive distributor agreements in key markets (China) to accelerate scale.
• Product maturity and segment posture: The business is hardware-led with active commercial deployments; the company is both a seller of systems and an enabler of recurring services and disposables.

If you want a consolidated view of customers and commercial signals, visit https://nullexposure.com/ for our analysis hub.

Commercial implications: upside and risk for investors

• Upside: Distributor exclusivity in China with MicroPort EP opens a large market and leverages local commercial strength without proportional expansion of SG&A in-country. Hospital adoptions like Klinikum Fürth and Penn Presbyterian validate clinical and commercial acceptance at flagship sites, which is the pathway to recurring consumable sales.
• Risk: Capital-deployment cycles and hospital budgeting impose revenue lumpiness; each system sale has a long lead time and can be deferred during economic weakness, consistent with the company’s own risk disclosures about financing for capital projects.
• Operational leverage: Success depends on converting system placements into recurring consumable and service revenues—this is the practical lever for margin improvement and valuation multiple expansion.

Bottom line and next steps for investors

Stereotaxis operates a classic capital-equipment business with a recurring-revenue back book and a hybrid direct/distributor model that supports global expansion. Key positive signals include flagship hospital adoptions and an exclusive China distributor; key risks remain long sales cycles and capital intensity at the front end. For analysts and operators tracking STXS, focus on the rate of system placements, conversion of placements into recurring revenue, and geographic scaling through distributors.

For a centralized view of these customer relationships and ongoing monitoring, visit https://nullexposure.com/. If you want regular briefings and relationship maps for investment diligence, sign up at https://nullexposure.com/ to get notified when coverage updates are posted.